维普中文期刊产品整合服务
15篇 您的检索式:作者名="Hasenburg A"
    题名 作者 年代 出处 被引量
1Expression of focal adhesion kinase in patients with endometrial cancer: a clinieopathologic study 显示文摘Gabriel B Hasenburg A Waizenegger M 2009Int J Gynecol Cancer2009,19,7:1
2Histologic and immunohistochemical analysis of tissue response to adenovirusmediated herpes simplex thymidine kinase gene therapy of ova-rian cancer显示文摘Hasenburg A Fischer DC Tong XW 2002Int J Gynecol Cancer2002,12,1:1
3信号转导和转录活化因子-1在上皮性卵巢癌中的表达及其与预后的关系显示文摘目的:探讨信号转导和转录活化因子(signal transducer and activator of transcription,STAT)-1在上皮性卵巢癌组织中的表达及其与预后的关系。方法:应用显微切割法从石蜡切片标本中提取mRNA,实时荧光定量PCR(real-time fluorogentic quantitative PCR,RFQ-PCR)和免疫组织化学方法检测105例原发性卵巢上皮癌和29例正常卵巢组织中STAT-1 mRNA及蛋白的表达,并分析其蛋白表达与预后的相关性。结果:上皮性卵巢癌组织中STAT-1 mRNA的表达高于正常卵巢组织[(0.96±1.05)vs(0.46±0.57),P=0.032],但mRNA表达水平与卵巢癌的手术分期、病理分级以及生存时间无关(P>0.05);上皮性卵巢癌组织中STAT-1和P-STAT-1蛋白的阳性表达率分别为72.4%和71.9%,显著高于正常卵巢组织(P<0.05),但蛋白表达水平与病理分级和手术分期无明显相关性(P>0.05)。在行辅助泰素化疗的病例组中STAT-1和P-STAT-1蛋白高表达患者的预后较好,总的生存时间长于低表达患者(P<0.05);STAT-1蛋白高表达的卵巢癌患者无瘤生存时间明显长于低表达患者(P<0.01)。结论:STAT-1在上皮性卵巢癌中存在异常表达,与紫杉醇类药物化疗后的预后密切相关。STAT-1可能是抑制肿瘤细胞生长的关键因子之一。沈怡 LASSMANN S HASENBURG A GERALD G MARTIN W 王泽华 2009肿瘤2009,29,8:1
4Histologic nohistochemieal analysis of tissue response to herpes simplex thymidine kinase gene therapy of ovarian cancer 显示文摘Hasenburg A Fischer DC Tong XW 2002Int J Gynecol Cancer2002,12,1:1
5Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage Ⅲ ovarian carcinomas: relevance of clonal selection of T lymphocytes 显示文摘Stumpf M Hasenburg A Riener MO 2009Br J Cancer2009,101,9:1
6Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer 显示文摘Hasenburg A Tong XW Rojas - Martinez A 2000Cancer Gene Ther2000,7,6:1
7Are individual differences of attachment predicting bereavement outcome after perinatal loss? A prospective cohort study 显示文摘Scheidt CE Hasenburg A Kunze M 2012J Psychosom Res2012,73,5:1
8Five years of exemestane as initial therapy compared to 5 years of ta- moxifen followed by exemestane: 'the TEAM trial, a prospective, randomized, phase Ill trial in postmenopausal women with hormone-sensitive early breast cancer 显示文摘Rea D Hasenburg A Seynaeve C 2009Cancer Res2009,69,24:1
9Histologic andimmunohistochemical analysis of tissue response to adenovirus- mediated herpes simplex thymidine kinase gene therapy of ovarian cancer显示文摘Hasenburg A Fischer DC Tong XW 2002Int J Gynecol Cancer2002,12,1:1
10European experience with a novel noninvasive sensor for intra-amniotic or extra- amniotic evaluation of fetal oxygen saturation显示文摘Hasenburg A Biuerle M Waterman D Journal of the Society for Gynecologic In Jestigation 20f)30,10,:1
11Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer:expression ofcoxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5显示文摘Hasenburg A Fischer DC Tong XW 2003J Soc Gynecol Investig2003,10,1:1
12Histologic and immunohistochemical analysis of tissue response to adenovirus - mediated herpes simplex thymidine kinase gene therapy of ovarian cancer显示文摘Hasenburg A Fischer DC Tong XW 2002Int J Gynecol Cancer2002,12,1:1
13Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer显示文摘Hasenburg A Fischer DC Tong XW 0,,:1
14Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer:2.5-year follow-up显示文摘Hasenburg A Tong XW Fischer DC 0,,:1
15Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer显示文摘Hasenburg A Fischer DC Tong X 2002Int J Gynecol Cancer2002,12,:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费